Stryker Corporation (SYK) Stock: Price, Forecast & Analyst Target
Stryker Corporation (SYK) — MoonshotScore 80/100 (Exceptional band), calculated Nov 18, 2026. Price $318.15 (+0.19%), as of the Nov 18, 2026 trading session; market cap $121B. Expected results Feb 4, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Stryker Corporation · SYK · NYSE · Healthcare · Medical - Devices
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered): Stryker sells orthopedic implants, surgical equipment, neurovascular devices, patient-handling systems and recurring-use hospital products rather than relying on a narrow implant franchise. The case depends on whether procedure demand and hospital capital spending can keep lifting revenue while cash generation absorbs a debt load that materially exceeds liquid resources.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Stryker (SYK)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and durable growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Full; Growth Durability: Compounding; Momentum: Rising.
- quarterly revenue $6.52B (Q3 FY2026, quarter ended Sep 2026)
- EPS beat 6 of the last 8 reports
- expected results Feb 4, 2027
Helping: business quality, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 80 | Exceptional | |
| 80 | Exceptional | |
| 80 | Exceptional | |
| 80 | Exceptional | |
| 80 | Strong | |
| 80 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $318.15 | |
| Change on the day | +0.19% | |
| 52-week range | $267.00–$389.33 | |
| Market capitalisation | $121B | — |
| Price / earnings (trailing) | 33.60 | |
| Shares traded on the day | 3.25M | |
| Beta (volatility vs the S&P 500) | 0.78 |
Why Stryker scores 80
Share price, last 12 months -17.1%
$373.42 $309.64
What the price assumes
10.6% a year of free-cash-flow growth for ten years is what a $117.88B market value ( snapshot) asks for.
The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $4.57B. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 9 of the last 12 reports (2024–2026); the stock still fell the next session after 5 of those beats. Average first-session move: 4.0% either way.
- +6.7%Jan ’24
- -3.2%Apr ’24
- -1.7%Jul ’24
- +2.1%Oct ’24
- -2.2%Jan ’25
- +1.1%May ’25
- -5.6%Jul ’25
- -3.6%Oct ’25
- +3.3%Jan ’26
- -6.5%Apr ’26
- -7.5%Jul ’26
- -4.0%Oct ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| In line | Miss | -4.0% | +10.2% | |
| Beat | In line | -7.5% | -4.2% | |
| Miss | Miss | -6.5% | -6.6% | |
| Beat | In line | +3.3% | +1.3% | |
| Beat | In line | -3.6% | -4.3% | |
| Beat | Beat | -5.6% | -6.0% | |
| Beat | Beat | +1.1% | +2.3% | |
| Beat | Beat | -2.2% | -1.9% | |
| Beat | Beat | +2.1% | +3.9% | |
| In line | In line | -1.7% | -3.2% | |
| Beat | Beat | -3.2% | -2.0% | |
| Beat | Beat | +6.7% | +8.0% |
Beating the estimate has not been enough: the stock fell after 5 of the last 9 beats. The bar it has to clear is the whisper number, not the published one.
What management is saying differently
Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.
- New this call: “against strong”, “knee market” — none of them came up in Q2 FY2026.
- Gone quiet: “full commercial”, “organic growth”, “capital products” — regular themes last call, absent this time.
The tone held steady from one call to the next; what changed is the subject matter, not the confidence.
Our track record on this stock
Since the score went from 79 to 80 while the share price moved -2.9% through .
| Date | Band | 3 months | 6 months | Call |
|---|---|---|---|---|
| Exceptional → Strong | — | — | — | |
| Strong → Exceptional | — | — | — | |
| Exceptional → Strong | — | — | — | |
| Strong → Exceptional | — | — | — |
None of the 4 band changes we have recorded has been graded yet; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 69% of 52 rate it a buy; the average target sits +12.1% from the price of $318.15.
- Last 90 days: 0 upgrades and 1 downgrade among 20 rating actions.
- Our signals: Exceptional band; strongest pillar Business Quality (88), weakest Valuation (47).
Here we and the crowd agree. Where we differ is on price: our Valuation reading is more cautious than the analysts' targets.
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Stryker (SYK): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Stryker (SYK), and what does it report?
Short answer · as of
Hospitals and medical professionals buy Stryker products for joint replacement, trauma, spine, surgery, emergency care, patient handling and neurovascular treatment.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
Demand therefore comes from procedures, equipment purchases and consumption of disposable or reprocessed devices, with company subsidiaries and distributors carrying the portfolio across international markets.
Stryker is not primarily a hip-and-knee implant company. MedSurg and Neurotechnology contributes more revenue than Orthopaedics, so reported sales blend implant demand with hospital capital purchases, surgical workflows, emergency care and recurring-use products.
What do the latest results show for Stryker (SYK)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $6.52B.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
The latest quarter delivered higher revenue, gross profit, operating profit, net income and diluted earnings than the comparable period. It also marked a sharp recovery from the preceding quarter, when revenue and earnings fell short of expectations; the latest release moved revenue back above expectations and earnings comfortably ahead.
Across the annual series, revenue advanced throughout the reported span while research spending also rose. Net income followed a less even path, which makes operating leverage and expense control important alongside sales growth.
Management attributes the outlook to acute and emergent procedure exposure, durable demand for capital products, modestly favorable pricing and a potentially helpful currency effect. Those are management’s stated supports; the reported improvement itself is visible in revenue, profit and cash flow.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $6.52B Oct 29, 2026
- Latest report · revenue estimate
- $6.62B Oct 29, 2026
- Latest report · revenue vs estimate
- Below estimate Oct 29, 2026
- Latest report · EPS vs estimate
- Below estimate Oct 29, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 29, 2026 | $6.52B | $6.62B | $3.5200 | $3.5500 |
| Jul 30, 2026 | $6.59B | $6.58B | $3.6900 | $3.4900 |
| Apr 30, 2026 | $6.02B | $6.34B | $2.6000 | $2.9800 |
| Jan 29, 2026 | $7.17B | $7.12B | $4.4700 | $4.4000 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $6.52B | $753M | $1.96 (diluted) |
| Q2 FY2026 | $6.59B | $1.28B | $3.31 (diluted) |
| Q1 FY2026 | $6.02B | $745M | $1.93 (diluted) |
| Q4 FY2025 | $7.17B | $849M | $2.20 (diluted) |
What are the financial strengths and risks for Stryker (SYK)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
Stryker generates substantial operating cash flow after capital spending, and the latest quarter improved markedly from the preceding period. Liquidity ratios indicate near-term obligations are covered, while the quality and distress screens remain supportive.
The balance sheet is not cash rich relative to borrowings: total debt stands well above cash and investments, leaving the company in a net-debt position. Cash has recovered from the preceding quarter but remains below the opening level of the reported history, so repurchases compete with debt reduction and other uses of capital.
A downturn in procedure activity would pressure implant and intervention products, while weaker hospital capital budgets would affect equipment demand. The broad portfolio spreads exposure across clinical categories, but much of it still depends on healthcare institutions continuing procedures and purchasing systems.
What should you watch next at Stryker (SYK)?
Short answer · as of
The next earnings report is expected on Feb 4, 2027.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
Watch whether revenue and operating profit sustain the latest rebound rather than reverting toward the preceding quarter’s weaker result. The scheduled earnings release offers the clearest near-term check, while analyst estimates assume continued expansion in revenue and earnings across the forecast horizon.
Organic sales growth, capital-product demand, pricing and currency are the operating markers management has identified. Cash conversion deserves equal attention because management plans to resume repurchases even as debt remains materially above cash and investments.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Stryker compare with its peers?
Short answer
Stryker's score ranks 8th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
Stryker combines orthopedic implants with surgical equipment, navigation, endoscopy, patient handling, emergency care, neurovascular devices, biosurgery products and device reprocessing. That breadth creates a different demand mix from a pure implant manufacturer or a stand-alone capital-equipment vendor.
MedSurg and Neurotechnology is the larger reported business, while Orthopaedics supplies the implant and trauma exposure commonly associated with the company. Acute and emergent procedures can support demand when discretionary procedures soften, although hospital purchasing remains a shared link across much of the portfolio.
| Company | Price | Market value | Score |
|---|---|---|---|
| $105.23 Nov 18, 2026 | $60.5B | 93 5-pillar Nov 18, 2026 | |
| $80.19 Nov 19, 2026 | $29.9B | 93 5-pillar Nov 18, 2026 | |
| $47.12 Nov 18, 2026 | $113B | 87 5-pillar Nov 18, 2026 | |
| $259.57 Nov 18, 2026 | $25.2B | 87 5-pillar Nov 18, 2026 | |
| $443.89 Nov 18, 2026 | $240B | 84 5-pillar Nov 18, 2026 | |
| $30.32 Nov 18, 2026 | $12.7B | 84 5-pillar Nov 18, 2026 | |
| $100.72 Nov 18, 2026 | $129B | 81 5-pillar Nov 18, 2026 | |
| Stryker (SYK) — this page | $318.15 | $121B | 80 |
| $103.32 Nov 18, 2026 | $19.6B | 79 5-pillar Nov 18, 2026 | |
| $29.27 Nov 19, 2026 | $28.6B | 78 5-pillar Nov 18, 2026 | |
| $43.64 Nov 18, 2026 | $63.3B | 77 5-pillar Nov 18, 2026 | |
| $168.98 Nov 18, 2026 | $210B | 72 5-pillar Nov 18, 2026 | |
| $228.58 Nov 18, 2026 | $161B | 71 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $309.00 – $407.00
- Consensus target
- $356.69
- Median target
- $364.50
Consensus record · Captured .
Measured against a quoted price of $318.15 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 6, 2026
- Transactions
- 48
- Identified insiders
- 8
- Purchases
- 0
- Sales
- 40
- Other transactions
- 8
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held SYK in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Fundsmith | Terry Smith | Q3 2026 | 5.70% | $735.98M | Trimmed −8.3% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Stryker (SYK)?
What Investors Ask About Stryker (SYK) — Healthcare
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered); the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Is Stryker mainly a hip-and-knee implant company?
MedSurg and Neurotechnology contributes more revenue than Orthopaedics. Joint replacement remains important, but surgical equipment, emergency care, patient handling, neurovascular products and recurring-use devices make Stryker a broader hospital supplier.
How do Stryker capital products affect its revenue profile?
Capital products tie part of revenue to hospital equipment purchasing rather than procedure volume alone. Management describes demand for those products as durable, making order momentum an important test of the outlook.
Why does Stryker’s MedSurg and Neurotechnology mix matter?
The segment carries the larger share of company revenue and spans surgical equipment, patient handling, emergency care and neurotechnology. Its scale means Stryker’s results cannot be read solely through orthopedic procedure trends.
Can Stryker fund resumed share repurchases while carrying debt?
Operating cash generation provides capacity for repurchases, and management has announced plans to resume them. Debt nevertheless exceeds cash and investments by a wide margin, so subsequent cash conversion and balance-sheet movement will show the trade-off.
What is the SYK stock price today?
The last price recorded for Stryker Corporation (SYK), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the SYK price target?
The analyst consensus price target for Stryker Corporation (SYK), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 43 figures on this page — 1 from SEC filings and earnings calls, 36 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold SYK
Funds in our ETF coverage that list SYK among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Jensen Quality Growth ETF (JGRW) | 4.20% |
